

**To:** BUCHAREST STOCK EXCHANGE FINANCIAL SUPERVISORY AUTHORITY

## CURRENT REPORT 05/2024

According to Law nr. 24/2017 regarding issuers of financial instruments and market operations, ASF regulation nr. 5/2018 regarding the issuers of financial instruments and market operations and/or the Bucharest Stock Exchange Rulebook for Multilateral Trading System.

Date of report	13.02.2024
Name of the Company	NOROFERT S.A.
Registered Office	Bucharest Str. Lt. Av. Şerban Petrescu Nr. 20, Ground Floor,
	Room 1 and 2, District 1
Phone	0753 157 858
Email	investitori@norofert.ro
Registration nr. with Trade Registry	J40/4222/2000
Fiscal Code	RO12972762
Subscribed and paid share capital	6,952,486 lei
Total number of shares	17,381,215
Market where securities are traded	MTS AeRO Premium, symbol NRF for shares
	Bonds-SMT, symbol NRF25 for bonds

**Important events to be reported:** Completion of the first stage of the laboratory for research and multiplication of microorganisms

The management of Norofert S.A., hereinafter referred to as the Company informs the market about the completion of the first stage of the laboratory for research and multiplication of microorganisms for use in agriculture. The laboratory is located in the premises of the input factory in Filipestii de Padure, owned by the Company, and is the only one of its kind in Romania.

The research and development of new products represents for the Company the main growth vector in the medium and long term, the strongest differentiator in a European market where the vast majority of manufacturers do not have a research department in the company. This laboratory has the capacity not only to produce raw materials needed for the factory but also to sell strains of microorganisms, in liquid or solid form, with technologies adapted to the requirements of local and international markets.

An important aspect of this first stage is the close collaboration between the team of researchers and technicians of the Company and the Faculty of Biotechnologies within the University of Agricultural Sciences and Veterinary Medicine (USAMV) Bucharest. Thus, the Company has access to scientific expertise and university resources contributing to the isolation and development of microorganisms owned and registered in its name.

This first stage of the project marks the completion of the construction of a medium-sized laboratory, representing an advanced and well-equipped technological space, in which the Company invested 3 million lei. The second stage of the project will start towards the end of 2024, and the total value of the investment will amount to over 6 million lei.





## PRESIDENT OF THE BOARD OF DIRECTORS

Popescu Vlad Andrei